PRLD
NASDAQ · Biotechnology
Prelude Therapeutics Inc
$3.91
+0.04 (+0.90%)
Open$3.85
Previous Close$3.88
Day High$3.98
Day Low$3.72
52W High$6.83
52W Low$1.04
Volume—
Avg Volume551.2K
Market Cap309.24M
P/E Ratio—
EPS$-0.73
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+140.9% upside
Current
$3.91
$3.91
Target
$9.42
$9.42
$6.99
$9.42 avg
$10.52
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 12.59M | 132.26M | 127.36M |
| Net Income | -103,177,924 | 2.80M | 2.65M |
| Profit Margin | -819.6% | 2.1% | 2.1% |
| EBITDA | -106,657,356 | 4.42M | 4.16M |
| Free Cash Flow | — | 2.17M | 2.21M |
| Rev Growth | — | +3.8% | -1.6% |
| Debt/Equity | — | 0.63 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |